Total Payments
$97,317
2024 Payments
$1,452
Companies
68
Transactions
815
Medicare Patients
1,029
Medicare Billing
$413,778
Payment Breakdown by Category
Other$59,435 (61.1%)
Travel$16,585 (17.0%)
Food & Beverage$15,058 (15.5%)
Consulting$5,530 (5.7%)
Education$540.83 (0.6%)
Gifts$168.83 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $52,820 | 29 | 54.3% |
| Travel and Lodging | $16,585 | 60 | 17.0% |
| Food and Beverage | $15,058 | 688 | 15.5% |
| Consulting Fee | $5,530 | 5 | 5.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $5,000 | 2 | 5.1% |
| Long term medical supply or device loan | $1,615 | 18 | 1.7% |
| Education | $540.83 | 12 | 0.6% |
| Gift | $168.83 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lexicon Pharmaceuticals, Inc. | $61,453 | 113 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $12,013 | 158 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $11,376 | 73 | $0 (2024) |
| Advanced Accelerator Applications | $1,468 | 4 | $0 (2021) |
| PUMA BIOTECHNOLOGY, INC. | $1,185 | 8 | $0 (2021) |
| Incyte Corporation | $923.19 | 21 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $795.91 | 42 | $0 (2024) |
| Celgene Corporation | $790.55 | 42 | $0 (2024) |
| Janssen Biotech, Inc. | $724.43 | 27 | $0 (2024) |
| TerSera Therapeutics LLC | $573.80 | 25 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,452 | 68 | AstraZeneca Pharmaceuticals LP ($214.07) |
| 2023 | $1,801 | 72 | Novartis Pharmaceuticals Corporation ($446.40) |
| 2022 | $3,684 | 93 | Novartis Pharmaceuticals Corporation ($2,123) |
| 2021 | $3,987 | 88 | Advanced Accelerator Applications ($1,410) |
| 2020 | $1,411 | 61 | Novartis Pharmaceuticals Corporation ($353.48) |
| 2019 | $2,776 | 96 | Puma Biotechnology, Inc. ($1,131) |
| 2018 | $18,811 | 130 | AstraZeneca Pharmaceuticals LP ($9,845) |
| 2017 | $63,397 | 207 | Lexicon Pharmaceuticals, Inc. ($54,633) |
All Payment Transactions
815 individual payment records from CMS Open Payments — Page 1 of 33
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 12/12/2024 | TerSera Therapeutics LLC | Xermelo (Drug) | Food and Beverage | In-kind items and services | $22.93 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $28.74 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $20.12 | General |
| Category: HEMATOLOGY | ||||||
| 11/21/2024 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $23.29 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.23 | General |
| 11/05/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $29.74 | General |
| Category: Oncology | ||||||
| 11/04/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.15 | General |
| Category: ONCOLOGY | ||||||
| 10/15/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $15.84 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $25.89 | General |
| Category: Oncology | ||||||
| 10/08/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $38.79 | General |
| Category: Oncology | ||||||
| 10/07/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $24.58 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/01/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: Oncology | ||||||
| 09/24/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: Oncology | ||||||
| 08/27/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $36.48 | General |
| Category: HORMONE THERAPY | ||||||
| 08/26/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $18.91 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $28.39 | General |
| Category: Oncology | ||||||
| 08/19/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $27.60 | General |
| Category: Oncology | ||||||
| 08/15/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: Oncology | ||||||
| 08/06/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $30.14 | General |
| 08/05/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $13.57 | General |
| 07/29/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.99 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 186 | 819 | $103,501 | $68,860 |
| 2022 | 9 | 246 | 1,071 | $161,729 | $107,611 |
| 2021 | 9 | 276 | 1,245 | $148,107 | $109,853 |
| 2020 | 10 | 321 | 1,662 | $171,759 | $127,454 |
Total Patients
1,029
Total Services
4,797
Medicare Billing
$413,778
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 61 | 295 | $69,348 | $47,524 | 68.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 13 | 92 | $17,940 | $10,398 | 58.0% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 38 | 139 | $10,877 | $7,815 | 71.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 147 | $3,831 | $1,927 | 50.3% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 12 | 19 | $1,124 | $823.46 | 73.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 50 | 127 | $381.00 | $373.38 | 98.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 67 | 350 | $82,250 | $57,290 | 69.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 11 | 122 | $26,445 | $16,743 | 63.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 26 | 140 | $27,700 | $16,454 | 59.4% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 31 | 91 | $7,320 | $5,386 | 73.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 19 | 19 | $4,935 | $3,890 | 78.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 11 | 52 | $6,240 | $3,513 | 56.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 11 | 33 | $3,234 | $2,166 | 67.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 13 | 130 | $3,204 | $1,771 | 55.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 57 | 134 | $402.00 | $397.14 | 98.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 72 | 359 | $73,080 | $54,854 | 75.1% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 11 | 121 | $24,630 | $18,054 | 73.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 18 | 155 | $23,881 | $17,323 | 72.5% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time per calendar month | Office | 2021 | 48 | 282 | $14,656 | $10,705 | 73.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 17 | 17 | $4,392 | $3,563 | 81.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 13 | 38 | $3,570 | $2,749 | 77.0% |
| 99439 | Chronic care management services, each additional 20 minutes of clinical staff time per calendar month | Office | 2021 | 20 | 30 | $1,730 | $1,079 | 62.4% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 13 | 74 | $1,661 | $1,018 | 61.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 64 | 169 | $507.00 | $507.00 | 100.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 68 | 296 | $53,576 | $39,929 | 74.5% |
About Dr. Hal Gerstein, MD
Dr. Hal Gerstein, MD is a Hematology & Oncology healthcare provider based in Great Neck, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790874121.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hal Gerstein, MD has received a total of $97,317 in payments from pharmaceutical and medical device companies, with $1,452 received in 2024. These payments were reported across 815 transactions from 68 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($52,820).
As a Medicare-enrolled provider, Gerstein has provided services to 1,029 Medicare beneficiaries, totaling 4,797 services with total Medicare billing of $413,778. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Great Neck, NY
- Active Since 10/12/2006
- Last Updated 11/15/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1790874121
Products in Payments
- Xermelo (Drug) $57,046
- IMFINZI (Drug) $10,086
- SANDOSTATIN LAR (Drug) $3,400
- AFINITOR (Drug) $3,138
- LUTATHERA (Drug) $3,120
- KISQALI (Drug) $2,041
- Nerlynx (Drug) $1,151
- OPDIVO (Biological) $632.38
- LYNPARZA (Drug) $476.37
- TAGRISSO (Drug) $386.58
- VERZENIO (Drug) $339.42
- DARZALEX (Biological) $332.31
- SOMATULINE DEPOT (Drug) $307.90
- JAKAFI (Drug) $300.29
- PROMACTA (Drug) $296.60
- IMBRUVICA (Drug) $294.06
- Revlimid (Drug) $268.76
- Enhertu (Drug) $253.51
- BENDEKA (Drug) $248.75
- KEYTRUDA (Biological) $231.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.